共 186 条
[1]
Seage GR(2001)Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET vaccine preparedness study Am J Epidemiol 153 619-627
[2]
Holte SE(2008)The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials J Acquir Immune Defic Syndr 48 82-89
[3]
Metzger D(2018)Randomised controlled trials – the gold standard for effectiveness research: study design: randomised controlled trials BJOG: An International Journal of Obstetrics and Gynaecology 125 1716-193
[4]
Koblin BA(1998)Why are randomised controlled trials important? Br Med J 316 201-214
[5]
Gross M(2016)Consort 2010 statement: extension to randomised pilot and feasibility trials BMJ 355 i5239-501
[6]
Celum C(2012)Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of menwho report sex with men, sex workers, and youth J Acquir Immune Defic Syndr 59 185-4
[7]
Djomand G(2000)Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? J Hum Virol 3 193-242
[8]
Metch B(2005)Participant retention in clinical trials of candidate HIV vaccines J Acquir Immune Defic Syndr 39 499-446
[9]
Zorrilla CD(2016)The 90 90 90 strategy to end the HIV pandemic by 2030: can the supply chain handle it? J Int AIDS Soc 19 1-242
[10]
Donastorg Y(2014)High HIV risk in a cohort of male sex workers from Nairobi Kenya Sex Transm Infect 90 237-2213